STEVEN EPPERSON: Open Payments
NPI 1053074138 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$776 in 36 payments from 11 companies in 2025. Trend: 2023 $162 · 2024 $463 · 2025 $776
Food & beverage: $776
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $162 |
| Alkermes, Inc. | 6 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $86 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| E.R. Squibb & Sons, L.L.C. | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Janssen Pharmaceuticals, Inc | 2 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Indivior Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $24 |
Products named: INGREZZA, ARISTADA, FANAPT, ABILIFY ASIMTUFII, COBENFY, INVEGA SUSTENNA, CAPLYTA, AUSTEDO XR.
Industry payments across AZ — which companies pay providers there.
